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Abstract Inhibition of thrombin by heparin cofactor II (HCII)
is accelerated 1000-fold by heparin or dermatan sulfate. To
investigate the contribution of basic residues of the A helix of
HCII to this activation, we constructed amino acid substitutions
(K101Q, R103L, and R106L) by site-directed mutagenesis.
K101Q greatly reduced heparin cofactor activity and required
a more than 10-fold higher concentration of dermatan sulfate to
accelerate thrombin inhibition compared with wild-type re-
combinant HCII. Thrombin inhibition by R106L was not sig-
ni¢cantly stimulated by dermatan sulfate. These results provide
evidence that basic residues of the A helix of HCII (Lys101 and
Arg106) are necessary for heparin- or dermatan sulfate-acceler-
ated thrombin inhibition. + 2002 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Heparin cofactor II (HCII) is a serine protease inhibitor
(serpin) found in human plasma and selectively inhibits
thrombin [1]. The rate of thrombin inhibition by HCII is
signi¢cantly increased in the presence of glycosaminoglycans
(GAGs) such as heparin and dermatan sulfate [2]. The heparin
or dermatan sulfate binding site of HCII has been localized to
the D helix region [3^5]. In another heparin binding serpin,
antithrombin (AT), the heparin binding sites are included in
the cluster of basic amino acids in the A helix and the D helix
[6^9]. Although the role of the basic amino acids in the
D helix of HCII in thrombin inhibition stimulated by
GAGs has been extensively investigated [10,11], the contribu-
tion of basic amino acids in the A helix to GAG-mediated
thrombin inhibition has not been examined. Among basic
amino acids of the A helix of AT, Arg47 is responsible for
heparin binding and heparin-mediated thrombin inhibition
[6,7]. Since HCII contains Arg103 in the position equivalent
to Arg47 of AT, only the experiment with mutation of Arg103
of HCII has been performed. Mutation data have indicated
that Arg103 of HCII is not critical for heparin binding and
inhibition of thrombin by heparin or dermatan sulfate [5].
In this study, we performed competition assays using syn-
thetic peptides corresponding to amino acid residues in the
A helix and site-directed mutagenesis of three basic residues
(Lys101, Arg103, and Arg106). Based on these experiments, we
have demonstrated the roles of basic amino acids of the
A helix of HCII in heparin- or dermatan sulfate-mediated
thrombin inhibition.
2. Materials and methods
2.1. Materials
Human K-thrombin was purchased from Sigma (St. Louis, MO,
USA). Heparin (bovine lung) and dermatan sulfate (pigskin) were
from Seikagaku Kogyo Co. Ltd. (Tokyo, Japan). Chromogenic sub-
strate S-2238 was from Chromogenix (Mo«lndal, Sweden). Synthetic
peptides were obtained from Takara Shuzo Co. Ltd. (Kyoto, Japan).
Synthetic oligonucleotides used for mutagenesis were obtained from
Genset Oligos Japan (Kyoto, Japan). Heparin-Sepharose CL-6B resin
was from Amersham Pharmacia Biotech AB (Uppsala, Sweden).
2.2. Mutagenesis of HCII cDNA
The EcoRI fragment containing HCII full-length cDNA (gift from
Dr. D.M. Tollefsen, Washington University) was subcloned into the
EcoRI site of glutathione S-transferase (GST)-fusion expression vec-
tor pGEX-6P-1 (Amersham Pharmacia Biotech AB). The obtained
plasmid then underwent deletion of the 5P-untranslated region and
signal sequence region of HCII insert to express wild-type recombi-
nant HCII (rHCII). That is, glycine at the position 1 of HCII follows
the cleavage site of the PreScission1 Protease. The construct was
designated pGEX-6P-HCWT. The nucleotides at the junction of
pGEX-6P-1 and the 5P end of HCII insert are as follows: CAG*G-
GGCCCCTGGGATCCCCGGGGAGCAAAGGC (the codon for
Gly1 of HCII is underlined and the asterisk represents the cleavage
site (Gln*Gly) of the PreScission1 Protease). Mutagenesis yielding
Lys101CGln, Lys101CGlu, Arg103CLeu, and Arg106CLeu was per-
formed using the Quick change site-directed mutagenesis kit (Strata-
gene, La Jolla, CA, USA); mutagenic primers used in this procedure
were, for Lys101CGln, 5P-GCTTTTTCATGGCCAGAGCCGGATC-
CAGCG-3P and 5P-CGCTGGATCCGGCTCTGGCCATGAAAAA-
GC-3P ; for Lys101CGlu, 5P-GCTTTTTCATGGCGAGAGCCGGA-
TCCAGCGTC-3P and 5P-GACGCTGGATCCGGCTCTCGCCATG-
AAAAAGC-3P ; for Arg103CLeu, 5P-CATGGCAAGAGCCTGATC-
CAGCGTCTTAAC-3P and 5P-GTTAAGACGCTGGATCAGGCTC-
TTGCCATG-3P ; and for Arg106CLeu, 5P-GGCAAGAGCCGGAT-
CCAGCTTCTTAACATCCTCAACGCC-3P and 5P-GGCGTTGAG-
GATGTTAAGAAGCTGGATCCGGCTCTTGCC-3P. The nucleoti-
des in italics indicate the sites leading to codon substitutions. The
¢nal constructs were con¢rmed by sequencing using the chain termi-
nation method of Sanger et al. [12].
2.3. Puri¢cation of rHCII variants
rHCII was expressed in Escherichia coli BL21 cells and puri¢ed
from the cell lysates according to the puri¢cation instructions recom-
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mended by Amersham Pharmacia Biotech. Brie£y, the cell lysate
(from a 2 l culture) suspended in 20 ml of phosphate-bu¡ered saline
(PBS)-containing Complete1 Protease Inhibitor Cocktail (Roche Di-
agnostics GmbH, Mannheim, Germany) was sonicated and then cen-
trifuged. The supernatant was applied to a GSTrap FF column (5 ml,
Amersham Pharmacia Biotech) at 4‡C. The column was washed with
PBS and then substituted with 50 mM Tris^HCl, 150 mM NaCl,
1 mM EDTA and 1 mM dithiothreitol, pH 7.4 (PreScission1 Protease
bu¡er). The cleavage of rHCII from GST by PreScission1 Protease
(Amersham Pharmacia Biotech) was performed on the column. A 4.5
ml portion of PreScission1 Protease bu¡er containing 100 U of Pre-
Scission1 Protease was injected onto the column and the system
was incubated at 4‡C overnight. Prior to elution, a 1 ml GSTrap
FF column (pre-equilibrated with PreScission1 Protease bu¡er) was
connected downstream to the above 5 ml GSTrap FF proteolytic
cleavage column. rHCII cleaved from GST was eluted immediately
upon £ow startup with PreScission1 Protease bu¡er. The purity of
the ¢nal preparations was assessed by SDS^PAGE on 7.5% polyac-
rylamide gels stained with Coomassie blue. Protein concentrations
were determined with a Bio-Rad Protein Assay kit (Bio-Rad Labo-
ratories, Richmond, CA, USA).
2.4. Inhibition of thrombin by rHCII variants
In the absence of GAG, the second-order rate constants (k2) for
thrombin inhibition by various rHCII variants were determined under
pseudo ¢rst-order conditions as described previously [13]. The e¡ect
of heparin or dermatan sulfate on inhibition of thrombin by rHCII
variants was determined by incubating 250^500 nM rHCII variants
with 1.9 nM thrombin and various concentrations of heparin or der-
matan sulfate in 200 Wl of assay bu¡er (50 mM Tris^HCl, 150 mM
NaCl, and 0.1% bovine serum albumin, pH 8.4). After 5 min incuba-
tion at room temperature, 50 Wl of 1 mg/ml S-2238 was added, and the
residual thrombin activity was determined by measuring the change of
absorbance at 405 nm. Peptide competition assays were performed by
the addition of synthetic peptides (0.1^100 WM) to the assay mixture
containing 2.5 Wg/ml heparin or 25 Wg/ml dermatan sulfate.
2.5. Heparin-Sepharose a⁄nity chromatography
A 1 ml heparin-Sepharose column was equilibrated with 50 mM
NaCl, 50 mM Tris^HCl, pH 7.4. Each puri¢ed rHCII preparation was
diluted with 50 mM Tris^HCl, pH 7.4, to the NaCl concentration of
50 mM, and applied to the column. The column was then washed
with 5 ml of the starting bu¡er and eluted with a 20 ml gradient of
50^500 mM NaCl in 50 mM Tris^HCl, pH 7.4. Fractions of 1 ml were
collected and their absorbances were measured at 280 nm. The dena-
tured rHCII was detected in the column £ow-through. The salt con-
centration corresponding to peak elution was the average of three
runs.
3. Results
3.1. Competition assays with synthetic peptides
Table 1 lists the sequence of synthetic peptides correspond-
ing to amino acid residues in the helix structure of HCII
(helices A, D, E, F, and H). The peptides were tested for their
ability to compete with wild-type rHCII for heparin binding
in thrombin inhibition assays. Table 1 presents the results of
these experiments, which are expressed as the concentrations
of peptide (IC50) required to block half of the thrombin inhi-
bition activity of wild-type rHCII in the presence of heparin.
Among these peptides, KSR20 and EIT20 competed with
wild-type rHCII in the thrombin inhibition assays, with
KSR20 being more e¡ective in doing so. In contrast,
RVV15 did not interfere with heparin-catalyzed thrombin in-
hibition, although this peptide had four Arg residues and one
Lys residue. The results suggest that the speci¢c sequence of
the peptide, not merely its charge, is important for heparin
binding. In the presence of dermatan sulfate, KSR20 also
blocked inhibition of thrombin, with an IC50 of 17 WM. These
results suggest the possibility that heparin and dermatan sul-
fate may bind to positively charged amino acid residues in-
cluded in residues 101^120 of HCII. We then prepared three
rHCII mutants, K101Q, R103L, and R106L, which replaced
Lys101 with Gln, Arg103 with Leu, and Arg106 with Leu, re-
spectively.
3.2. Binding of rHCII variants to heparin-Sepharose
Heparin-Sepharose chromatography was performed to de-
termine the relative a⁄nities of the rHCII variants for heparin
(Table 2). Wild-type rHCII was eluted from the heparin-Seph-
arose column with a peak at 220 mM NaCl. R103L and
R106L did not a¡ect the ionic strength at which they eluted
from heparin-Sepharose. The results indicate that the positive
charge on the amino acid at position 103 or 106 of HCII is
not required for heparin binding when assessed by a⁄nity
chromatography. In contrast, K101Q was eluted from the
Table 1
Competition between HCII and synthetic peptides in heparin-mediated thrombin inhibition
Helix Name of synthetic peptide Sequence ICa50 (WM)
A KSR20 (101^120)b KSRIQRLNILNAKFAFNLYR 3.7
D EIT20 (175^194) EITTIHNLFRKLTHRLFRRN 18
E LLD13 (214^226) LLDFRTKVREYYF s 100
F KTN15 (242^256) KTNNHIMKLTKGLIK s 100
H RVV15 (357^371) RVVERWQKSMTNRTR s 100
aThe peptide concentration that blocked 50% of inhibitory activity was measured using inhibitory activity in the absence of peptide as the start-
ing point (0%) and thrombin activity in the absence of HCII as the endpoint (100%). Plots of thrombin activity versus peptide concentration
were typically sigmoidal.
bThe numbers in parentheses represent the positions of amino acid residues corresponding to those of HCII.
Table 2
Heparin a⁄nity of rHCII variants
rHCII variant Heparin a⁄nitya (mM NaCl)
Wild-type 220
K101Q 150
R103L 200
R106L 210
aHeparin a⁄nity is given as the salt concentration required for elu-
tion from a 1 ml column of heparin-Sepharose.
Table 3
Second-order rate constants for inhibition of thrombin by rHCII
variants in the absence of a GAG
rHCII variant k2 (M31 min31) %
Wild-type 8.09U103 100
K101Q 8.40U103 104
R103L 12.4U103 153
R106L 10.6U103 131
Assays were performed as described in Section 2. k2 values pre-
sented are the mean of at least three determinations.
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heparin-Sepharose column with a peak at 150 mM NaCl,
suggesting that K101Q has a decreased a⁄nity for heparin.
3.3. Inhibition of thrombin by rHCII variants in the absence or
presence of heparin or dermatan sulfate
As shown in Table 3, second-order rate constants (k2) of
these rHCII mutants for inhibition of thrombin in the absence
of GAG were similar to the value obtained for wild-type
rHCII. These ¢ndings provide evidence that the rHCII pro-
teins are folded properly, and that these reactive sites, in par-
ticular, are intact. The k2 value obtained for wild-type rHCII
(8.09U103 M31 min31) was 10-fold lower than the value re-
ported previously [13]. The di¡erences in rate constants may
be related to di¡erences in expression vector system and pu-
ri¢cation methods. The lower values may result from the im-
precision in the determination of rHCII concentration due to
the denatured protein.
The e¡ects of heparin or dermatan sulfate on the extent of
inhibition of thrombin by rHCII variants are shown in Fig. 1.
In these experiments, wild-type rHCII inhibited 50% of the
thrombin activity in the presence of 0.35 Wg/ml heparin or 4.3
Wg/ml dermatan sulfate. Most importantly, K101Q greatly
reduced heparin cofactor activity, which is consistent with
the observation that K101Q has a lower a⁄nity than wild-
type rHCII for heparin-Sepharose. In contrast, R103L and
R106L required only three-fold higher concentrations of hep-
arin than wild-type rHCII to inhibit 50% of thrombin activity.
These observations suggest that Lys101 is essential for heparin-
dependent thrombin inhibition.
In the presence of dermatan sulfate, thrombin inhibition by
R106L was not stimulated (Fig. 1, bottom). K101Q required
at least a 10-fold higher concentration of dermatan sulfate to
accelerate inhibition of thrombin in comparison with wild-
type rHCII. These results suggest that Arg106 and Lys101 are
necessary for dermatan sulfate-dependent thrombin inhibi-
tion. R103L, however, had no e¡ect on the ability of either
heparin or dermatan sulfate to accelerate the reaction, consis-
tent with the ¢ndings of Blinder et al. [5]. These results in-
dicate that Lys101 is required for heparin- and dermatan sul-
fate-dependent thrombin inhibition, and that Arg106 is
necessary for dermatan sulfate- but not heparin-mediated
thrombin inhibition. This suggests that the binding sites of
heparin or dermatan sulfate in the A helix of HCII are not
identical.
To con¢rm the importance of the positive charge at Lys101,
we constructed the mutant, K101E, which featured substitu-
tion of positively charged amino acid by negatively charged
amino acid. In the absence of GAG, the k2 value of K101E
for thrombin inhibition was 5.14U103 M31 min31, which was
slightly lower than that of wild-type rHCII. As shown in
Fig. 1, no acceleration of thrombin inhibition by K101E
was observed with either heparin or dermatan sulfate. These
¢ndings indicate that the positive charge at Lys101 is essential
for acceleration of thrombin inhibition of HCII by heparin or
dermatan sulfate.
4. Discussion
HCII is a serpin and is further classi¢ed as a heparin-bind-
ing serpin [14]. The current model of the mechanism of acti-
vation of HCII suggests that the amino-terminal acidic do-
main of HCII is freed from intramolecular interactions upon
heparin binding and interacts with exosite I on thrombin [15^
17]. The binding site of heparin to HCII is included in the
D helix and has been extensively investigated. In another ser-
pin, AT, the heparin binding site has been localized to the
A helix and the D helix and is known to undergo a conforma-
tional change upon binding of heparin. Moreover, it has been
reported that the heparin binding site of protein C inhibitor is
included in the H helix but not the D helix [18]. In HCII, the
cluster of basic amino acids lies within the A and H helices in
addition to the D helix [19]. In this study, a synthetic peptide
(KSR20) corresponding to the A helix of HCII (residues 101^
120) interfered with heparin- or dermatan sulfate-catalyzed
thrombin inhibition. The ability of KSR20 to interfere with
the reaction was stronger than that of a synthetic peptide
(EIT20) corresponding to the D helix of HCII (residues
175^194). The results obtained from peptide competition as-
says suggested that heparin or dermatan sulfate might bind to
amino acid residues included in the A helix of HCII.
K101Q exhibited a signi¢cant decrease in heparin-Sepha-
rose a⁄nity. K101Q almost lost the ability to accelerate
thrombin inhibition in the presence of heparin, and required
more than 10-fold higher concentrations of dermatan sulfate
to accelerate thrombin inhibition in comparison with wild-
Fig. 1. E¡ects of heparin and dermatan sulfate concentrations on
inhibition of thrombin by rHCII variants. Thrombin (1.9 nM) was
incubated with 250^500 nM rHCII variants in the presence of vari-
ous concentrations of heparin and dermatan sulfate. After 5 min,
residual thrombin activity was measured by adding S-2238 and ex-
pressed as a percentage of the control (in the absence of GAG).
Top is heparin; bottom is dermatan sulfate.
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type rHCII. Furthermore, K101E exhibited no acceleration of
thrombin inhibition by either heparin or dermatan sulfate.
These observations suggest that the binding sites of HCII
for heparin and dermatan sulfate contain Lys101, and that
the positive charge at Lys101 is essential for GAG-accelerated
thrombin inhibition.
R106L could not exhibit acceleration of thrombin inhibi-
tion with dermatan sulfate but did not a¡ect the heparin-ac-
celerated reaction. Furthermore, R106L was eluted from hep-
arin-Sepharose at the same ionic strength as wild-type rHCII.
These ¢ndings suggest that Arg106 plays a major role in the
stimulation of dermatan sulfate-mediated thrombin inhibition
but does not interact with heparin. The binding sites in the A
helix of HCII for the two GAGs are thus apparently not
identical, as found for the D helix of HCII [10].
R103L inhibited thrombin in the same manner as wild-type
rHCII in the presence of either heparin or dermatan sulfate.
In AT, Arg47 is essential for acceleration of thrombin inhibi-
tion by heparin. However, mutations in the equivalent posi-
tion in HCII (Arg103) produced di¡erent results. In the amino
acid sequence alignment of HCII and AT, the amino acid
corresponding to Lys101 in HCII is not found in AT [20].
Although there are no three-dimensional structural data for
HCII, it is possible that the side chain of Lys101 is exposed to
the surface of the HCII molecule and the side chain of Arg103
is oriented toward the inside of the molecule.
Liaw et al. have reported that release of the amino-terminal
domain of HCII by charge neutralization at ¢ve basic residues
of the D helix is insu⁄cient to fully stimulate inhibition of
thrombin [11]. It is possible that Lys101 and Arg106 are related
to the additional intramolecular interactions that constrain
the amino terminus. In addition, as elucidated for AT, HCII
may also undergo a conformational change of the reactive
center upon binding of GAG to the basic residues of the
A and D helices of HCII.
In summary, the basic residues of the A helix in HCII,
Lys101 and Arg106, contribute to acceleration of thrombin in-
hibition by GAGs. Our results have further de¢ned the spe-
ci¢c basic residues within HCII required for heparin- or der-
matan sulfate-accelerated inhibition of thrombin.
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